Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis

Pharmacology, Toxicology and Pharmaceutical Science

• Skin Leishmaniasis 100%
• Visceral Leishmaniasis 100%
• Leishmania donovani 100%
• Promastigote 100%
• Amphotericin B 100%
• Leishmania amazonensis 100%
• Infection 50%
• Leishmaniasis 50%
• Bagg Albino Mouse 50%
• Antimonial 50%
• Polyene 50%
• Pentamidine 50%
• Experimental Visceral Leishmaniasis 50%
• Experimental Cutaneous Leishmaniasis 50%
• Skin Infection 50%
• Skin Defect 50%

Keyphrases

• Leishmania Amazonensis 100%
• Visceral Leishmaniasis 100%
• Leishmania Donovani 100%
• Murine Cutaneous Leishmaniasis 100%
• Promastigote 50%
• Amphotericin B 50%
• Leishmaniasis 25%
• Cutaneous Leishmaniasis 25%
• Liver 25%
• Balb C Mice 25%
• Spleen 25%
• Response to Therapy 25%
• Cutaneous Lesions 25%
• Parasite Burden 25%
• Cutaneous Infection 25%
• Antimonials 25%
• Current Therapies 25%
• Failure Rate 25%
• Polyene Antifungals 25%
• New Water 25%
• Water-soluble 25%
• Pentamidine 25%
• Ear pinna 25%
• Log Reduction 25%

Immunology and Microbiology

• Cutaneous Leishmaniasis 100%
• Visceral Leishmaniasis 100%
• Promastigote 100%
• Leishmania amazonensis 100%
• Leishmania donovani 100%
• Infection 100%
• Leishmaniasis 50%
• Bagg Albino Mouse 50%
• Parasite Load 50%
• Body Weight 50%
• Pentamidine 50%